(Q33878643)

English

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Laura Ciccolallo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Cecilia Bozzetti

6

object named as

Cecilia Bozzetti

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Andrea Ardizzoni

9

object named as

Andrea Ardizzoni

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Michele Panebianco

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Elisa Fontana

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Daniele Zanoni

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Maria Michiara

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Enrico Maria Silini

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

0 references

publication date

10 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

117

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1837-1846

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21509760%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Breast carcinoma: Pattern of metastasis at autopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Brain metastases: the HER2 paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Brain metastases from breast cancer: identification of a high-risk group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Primary breast cancer phenotypes associated with propensity for central nervous system metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

The Use of Maximum Likelihood Estimates in χ2 Tests for Goodness of Fit

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Applying Cox regression to competing risks.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Survival among women with triple receptor-negative breast cancer and brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

21 January 2018

Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for brain relapse in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in CSF

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25771

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33878643&oldid=1966903930"